试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-18
Comparison of Respiratory Tolerance to I.V. Versus Sublingual Sedation During Bronchoscopy. (TORSIV)
编号:NCT01698892登记状态:提前终止企业 / 申办者:Nantes University Hospital
药物 / 成分:I.V Sedation、sublingual sedation
登记的停止原因(原文):End study
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-18
Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma
编号:NCT02530502登记状态:提前终止企业 / 申办者:Northwestern University
药物 / 成分:Laboratory Biomarker Analysis、Pembrolizumab、Radiation Therapy、Temozolomide
登记的停止原因(原文):The protocol was amendment to be stopped after phase I (phase 2 removed from protocol)
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-18
Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease
编号:NCT02743806登记状态:提前终止企业 / 申办者:Takeda
药物 / 成分:Vedolizumab
登记的停止原因(原文):Early Completed - Alternative Source of Drug Available
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-18
Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner
编号:NCT03618134登记状态:提前终止企业 / 申办者:Jonsson Comprehensive Cancer Center
药物 / 成分:Durvalumab、Modified Radical Neck Dissection、Quality-of-Life Assessment、Questionnaire Administration
登记的停止原因(原文):slow accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-18
Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
编号:NCT03624036登记状态:提前终止企业 / 申办者:Kite, A Gilead Company
药物 / 成分:brexucabtagene autoleucel、Fludarabine、Cyclophosphamide
登记的停止原因(原文):Development program terminated
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-18
CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia
编号:NCT03904251登记状态:提前终止企业 / 申办者:Jonsson Comprehensive Cancer Center
药物 / 成分:Gemtuzumab Ozogamicin、Liposome-encapsulated Daunorubicin-Cytarabine
登记的停止原因(原文):slow accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-18
Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
编号:NCT04329949登记状态:提前终止企业 / 申办者:Corcept Therapeutics
药物 / 成分:Relacorilant, 100 mg and 25 mg、Nab-paclitaxel
登记的停止原因(原文):The independent data monitoring committee found no safety issues, however the observed response rate did not meet the predefined threshold for continuing the study. The study was terminated by the Sponsor.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-18
Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)
编号:NCT04409873登记状态:提前终止企业 / 申办者:University of California, San Francisco
药物 / 成分:Oral-B Mouth Sore mouthwash、Crest Pro-Health Multi-Protection mouthwash、CloSYS Ultra Sensitive Rinse mouthwash、Distilled water
登记的停止原因(原文):The funder decided not to continue funding, causing enrollment to cease prematurely and curtailing originally planned analyses. Participants with any samples collected after the baseline pre-rinse samples were included in the analysis.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-18
A Study of Benralizumab in Patients With Eosinophilic Esophagitis
编号:NCT04543409登记状态:提前终止企业 / 申办者:AstraZeneca
药物 / 成分:Benralizumab、Matching placebo
登记的停止原因(原文):High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints. Given the lack of clear benefit in this patient population, study has been terminated.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-18
Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose
编号:NCT04715230登记状态:提前终止企业 / 申办者:InterveXion Therapeutics, LLC
药物 / 成分:IXT-m200、Lorazepam、Haloperidol
登记的停止原因(原文):Sponsor decision based on slower than anticipated enrollment leading to fund exhaustion.
查看官方原始记录 ↗